%PDF-1.4
%
19 0 obj
<>
endobj
16 0 obj
<>
endobj
65 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T18:04:26Z
2024-03-28T22:55:17-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T22:55:17-07:00
application/pdf
Heather
2002-651.suppl66
uuid:812eb93d-1dd2-11b2-0a00-640927bd3700
uuid:812eb941-1dd2-11b2-0a00-5b0000000000
endstream
endobj
5 0 obj
<>
endobj
6 0 obj
<>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
72 0 obj
[76 0 R]
endobj
73 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.01781 Tw 10 0 0 10 54 712.2551 Tm
[(recommendations, e.g., the followup from the COBRA)-177.3 (trial)]TJ
0 Tw 6.5 0 0 6.5 290.7501 715.5551 Tm
(1)Tj
-0.0188 Tw 10 0 0 10 54 700.2551 Tm
(suggests that the intensive combination treatment arm main-)Tj
0.02499 Tw 0 -1.2 TD
[(tains the dif)17.8 (ferential compared to the monotherapy arm. )]TJ
0.19141 Tw 1.2 -1.2 Td
(No doubt the role of the biologic agents will become)Tj
0.0804 Tw -1.2 -1.2 Td
[(better defined as their longterm side ef)17.8 (fect profile is docu-)]TJ
0.0007 Tw T*
(mented in followup studies. How these drugs will revise the)Tj
0.0358 Tw T*
[(current treatment protocol remains to be determined. )17.7 (While)]TJ
0.0013 Tw T*
(many issues remain controversial, there is one area of unan-)Tj
0.0388 Tw T*
(imous agreement \227 we are part of the most exciting era of)Tj
0 Tw T*
[(rheumatology)64.9 (.)]TJ
/TT1 1 Tf
-0.00011 Tc 12 -2.4 Td
[(P)73.9 (AUL)-220.2 (EMER)34.8 (Y)]TJ
/TT0 1 Tf
0 Tc (, )Tj
-0.00011 Tc 0.02499 Tw 6 0 0 6 244.7954 580.2551 Tm
[(MA, MD, FRCP)110.7 (,)]TJ
8 0 0 8 174 570.2551 Tm
[(ARC Professor of Rheumatology)64.8 (,)]TJ
0 -1.25 TD
(University of Leeds, )Tj
0 Tc T*
(Lead Clinician, )Tj
0.0072 Tw T*
[(Leeds T)69.8 (eaching )-17.8 (Hospital T)34.9 (rust, )]TJ
-0.00011 Tc 0.02499 Tw T*
(Leeds, UK. )Tj
/TT2 1 Tf
-15 -2.5 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. Emery)54.8 (, Department of Rheumatology)54.8 (,)]TJ
T*
[(Leeds General Infirmary)54.8 (, Old Nurses Home, Gr)36.7 (eat Geor)36.8 (ge Str)36.8 (eet, Leeds, )]TJ
0 Tc T*
(UK LS1 3EX.)Tj
0.0199 Tc 0.4653 Tw 33 28.0343 Td
(Symposium Participants)Tj
/TT0 1 Tf
[-0.4 (: Chair: P)91.7 (AUL)-698.5 (EMER)54.9 (Y)91.9 (; Panel: HILAR)54.9 (Y)]TJ
0 Tc 0.3391 Tw T*
(CAPELL, Consultant Rheumatologist, Centre for Rheumatic Disease,)Tj
-0.00011 Tc 0.05659 Tw T*
[(Royal Infirmary)64.8 (, Glasgow)64.8 (, Scotland; BARR)54.8 (Y)-269.6 (BRESNIHAN, Professor of)]TJ
0 Tc 0.29021 Tw T*
[(Rheumatology)64.9 (, Department of Rheumatology)64.9 (, St. )17.7 (V)60.1 (incent\222)54.9 (s University)]TJ
-0.00011 Tc 0.2793 Tw T*
(Hospital, Dublin, Ireland; JOACHIM KALDEN, Professor of Internal)Tj
0.07671 Tw T*
(Medicine, Director and Head of the Department for Internal Medicine III)Tj
0.00661 Tc 0.3683 Tw T*
[(and the Institute for Clinical Immunology)64.8 (, University of Erlangen-)]TJ
-0.00011 Tc 0.20399 Tw T*
[(Nurember)17.7 (g, Erlangen, Germany; MAXIME DOUGADOS, Professor of)]TJ
0.02 Tc 0.476 Tw T*
[(Rheumatology)65 (, Ren\351 Descartes University)65 (, Chief, Department of)]TJ
0.0031 Tc 0.3718 Tw T*
[(Rheumatology)64.8 (, H\364pital Cochin, Paris, France; JOSEF S. SMOLEN,)]TJ
-0.00011 Tc 0.12939 Tw T*
[(Professor of Rheumatology)64.9 (, University of )17.7 (V)60 (ienna, )17.7 (V)60 (ienna, )54.8 (Austria; LEO)]TJ
0.28239 Tw T*
[(V)129.1 (AN DE PUTTE, Professor of Internal Medicine and Rheumatology)64.9 (,)]TJ
0 Tc 0.02499 Tw T*
[(University Hospital, Nijmegan, )17.8 (The Netherlands.)]TJ
/TT1 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 318 570.5293 Tm
(REFERENCE)Tj
/TT0 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 325 560.5293 Tm
[(1.)-875 (Landewe RB, Boers M, )17.7 (V)111.1 (erhoeven )54.8 (AC, et al. COBRA)-220.1 (combination)]TJ
1.675 -1.25 Td
(therapy in patients with early rheumatoid arthritis: long-term )Tj
T*
[(structural benefits of a brief intervention. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(2002;46:347-56.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
0.02499 Tw 8 0 0 8 354.2144 35.9844 Tm
[(The Journal of Rheumatology 2002, V)110.8 (olume 29, Supplement 66)]TJ
0 Tw -37.5268 -0.0313 Td
(2)Tj
ET
0 0 0 0 scn
/GS0 gs
100.28 59.75 407.5 -10.83 re
f*
0.5 w
100.28 59.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
43 0 obj
<>
endobj
71 0 obj
<>
endobj
26 0 obj
<>
endobj
28 0 obj
<>
endobj
23 0 obj
<>
endobj
22 0 obj
<>
endobj
35 0 obj
<>stream
HV lޛ]1f;!7se/G̱v8vq0`9Bh9DRHI)%1u[ TԄ#E
Gp!P`߬
Dϟ7
o잁 S/R;,X0\
%}
hJM;xIbyyI&/]Wiݹo)1G4?9宥e;w|CF<0ƚrLYpqyt||_%XVmVO*۴WjyU'YUe$k>WʐXgpzp[q cׯݐNC>.CbV0E8N4x 1aE,A-cga|8$kSpB|*Fz}Q7
73RXd5aGy?KrU zNI"Zt"|#'M:%GZ=zÃ?y/Zl&8+f
ʵY_ؽt1Q6c4*c6:l}G_
=1qg`3n=3
g9.㊈P'VaqZzJ٫i]Haee6d{:f!ȓᏨ!k#DW[m2U>'K|yH~*u-DNVX*Bda6N1vp&"Jtٌ>eL&/(ezRy÷,o->ey]1{%
;!o'γAMxd#8E
GpjC<1QTJo;Q'>GYɑ/gerL!TTQGn-V-ժ=og+Íӊ2JkժgWT2
mdWbgh$3"|/b(bxM,ek86GԊ⚸-.ؙ=(K*|WnOҔu+X%MU*㕠@YlWv(('&PyVs Rz{|Z6O{Eij5^va:
$Ml[>i?C<|$qX!!>BZC|ȍ(o=HNjcJ$)\úDk]{>ҙZg*0'>F|Rz=g?x۳i]_.SS:%wLJLvqmcĴnth"ƈnL55mFOSj>O{zY3OO籧a;K٘k`uFn6E"k5="rqM*MнҐ7x
kʝv kZۑM.+Md{xd#kv4r#6%,2&\|w)M̶-#Mp1FZ[ف̘"(8o*|vfk&v9h]bFSF4kF5[
4fΘre+Xԛ(6&0W7aFihn5Oĵ79`Kͫ
B'#?RIKѣw|jHZ>Œ5@W+y̤U6c40BSo+Pa/XP ZZ~ h4xZl8~hmff9S6ڐ;df'
yc0@6r-[Sl
fDcvdg2`[?lK#Ox3*_۸Hݶ:KûMe{JRdyLT 9,>6ᢾF+A-)r^%s?QH$ ID6TK#ώC|F t\"#6'm*JVUͲuMcUqT۾?ill]b@rM%\9Q Mm.D7e9pȜ\i2AK>k۹ٛp>"1%պ^8}u
RZ>bm(fNS4p|?1弅@FQGqjm:{&vN9 ݘA^
Z!І-mEx
5$q,ڂԑ/P
uC7<ڵ FXiBJ[&Vmc3Qi~<~;9;l#Wׅ5Qɕ1Q $wQ5B[5D-v"4-Mv
Jn% >ZɅ,GW?h
5&@ !V@ bx;{xq< k2 T
@^ay=X=3fD^ +;1(?yy [; gv63I֡̀EীhX